INS and metabolic syndrome: Conversely, a loss of beneficial SCFA-producing bacteria (e.g., Faecalibacterium prausnitzii and Roseburia) is often noted in T2D and metabolic syndrome, potentially reducing SCFA-mediated benefits in insulin sensitivity and gut integrity [34].